Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Caribou Biosciences, Inc. - Common Stock
(NQ:
CRBU
)
1.590
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Caribou Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
December 24, 2025
Issued on behalf of GT Biopharma, Inc.
From
Equity Insider
Via
GlobeNewswire
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
December 01, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments
↗
November 03, 2025
Via
Stocktwits
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
November 03, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside
November 03, 2025
Via
AB Newswire
Topics
Artificial Intelligence
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today?
↗
November 03, 2025
Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.
Via
Benzinga
Gapping stocks in Monday's session
↗
November 03, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Discover the top movers in Monday's pre-market session.
↗
November 03, 2025
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 03, 2025
Via
Benzinga
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
November 03, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
November 03, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
↗
November 03, 2025
Via
Benzinga
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
November 02, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
October 04, 2025
As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for...
Via
MarketMinute
Topics
Artificial Intelligence
Climate Change
Economy
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
August 25, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences Inc (NASDAQ:CRBU) Posts Mixed Q2 2025 Earnings with Revenue Beat but Wider Loss
↗
August 12, 2025
Caribou Biosciences reports Q2 2025 earnings with revenue beating estimates at $2.67M but a wider EPS loss of -$0.58. Clinical updates expected in H2 2025.
Via
Chartmill
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 25, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
↗
June 20, 2025
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research
Via
Benzinga
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference
May 28, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 08, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference
May 06, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
April 24, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 10, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 06, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
CRBU DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important February 24 Deadline in Securities Class Action - CRBU
February 19, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
February 19, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
February 18, 2025
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights
February 15, 2025
From
Rosen Law Firm
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
